Genolmmune Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 10

Genolmmune Therapeutics General Information

Description

Developer of an advanced biotechnology designed to serve in the treatment of tumor immune cells. The company uses advanced life digital technology to stimulate the vitality of the human immune system against tumors and develop new advanced prevention and treatment programs targeting tumor-specific antigens to benefit patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, Building 5, Biomedical Park
  • No. 388, Gaoxin 2nd Road, New Technology Development Zone
  • Wuhan, Hubei 430079
  • China
+86 0755
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5th Floor, Building 5, Biomedical Park
  • No. 388, Gaoxin 2nd Road, New Technology Development Zone
  • Wuhan, Hubei 430079
  • China
+86 0755

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genolmmune Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 28-Dec-2022 Completed Generating Revenue
3. Later Stage VC 12-Aug-2022 Completed Generating Revenue
2. Early Stage VC (Series A1) 08-Dec-2020 $15.2M $33.1M Completed Generating Revenue
1. Early Stage VC (Series A) 20-Mar-2019 $17.9M $17.9M Completed Generating Revenue
To view Genolmmune Therapeutics’s complete valuation and funding history, request access »

Genolmmune Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
BGI Co-Win Corporate Venture Capital Minority
Kunshan Industrial Technology Research Institute Government Minority
TFTR Investment Corporate Venture Capital Minority
Forebright Capital PE/Buyout Minority
GL Ventures Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Genolmmune Therapeutics FAQs

  • When was Genolmmune Therapeutics founded?

    Genolmmune Therapeutics was founded in 2017.

  • Where is Genolmmune Therapeutics headquartered?

    Genolmmune Therapeutics is headquartered in Wuhan, China.

  • What industry is Genolmmune Therapeutics in?

    Genolmmune Therapeutics’s primary industry is Drug Discovery.

  • Is Genolmmune Therapeutics a private or public company?

    Genolmmune Therapeutics is a Private company.

  • What is Genolmmune Therapeutics’s current revenue?

    The current revenue for Genolmmune Therapeutics is .

  • How much funding has Genolmmune Therapeutics raised over time?

    Genolmmune Therapeutics has raised $41.9M.

  • Who are Genolmmune Therapeutics’s investors?

    BGI Co-Win, Kunshan Industrial Technology Research Institute, TFTR Investment, Forebright Capital, and GL Ventures are 5 of 10 investors who have invested in Genolmmune Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process